Annelien J. M. Zweemer

Annelien J. M. Zweemer

Auto-generated profile, based on publicly available information

Annelien J. M. Zweemer

Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Trends in Immunology
Verified
Journal Article
Closed access
AZAnnelien J.M. Zweemer
Annelien J.M. Zweemer
JTJimita Toraskar
Jimita Toraskar
LHLaura Heitman
Laura Heitman
AIAd Ijzerman
Ad Ijzerman

1 September 2011 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ZGZhan-Guo Gao
Zhan-Guo Gao
DVDennis Verzijl
Dennis Verzijl
AZAnnelien Zweemer
Annelien Zweemer
KYKai Ye
Kai Ye
AGAnikó Göblyös
Anikó Göblyös
Kenneth A. JacobsonKenneth A. Jacobson
Kenneth A. Jacobson

27 September 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MVMaris Vilums
Maris Vilums
AZAnnelien J. M. Zweemer
Annelien J. M. Zweemer
ZYZhiyi Yu
Zhiyi Yu
HVHenk de Vries
Henk de Vries
JHJulia M. Hillger
Julia M. Hillger
AIAd Ijzerman
Ad Ijzerman

23 July 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LHLaura Heitman
Laura Heitman
JVJacobus P. D. van Veldhoven
Jacobus P. D. van Veldhoven
AZAnnelien M. Zweemer
Annelien M. Zweemer
KYKai Ye
Kai Ye
JBJohannes Brussee
Johannes Brussee
AIAd Ijzerman
Ad Ijzerman

1 October 2013 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
AZAnnelien J. M. Zweemer
Annelien J. M. Zweemer
INIndira Nederpelt
Indira Nederpelt
HVHilde Vrieling
Hilde Vrieling
SHSarah Hafith
Sarah Hafith
MDMaarten L. J. Doornbos
Maarten L. J. Doornbos
LHLaura Heitman
Laura Heitman
The chemokine receptor CCR2 is a G protein–coupled receptor that is activated primarily by the endogenous CC chemokine ligand 2 (CCL2). Many different small-molecule antagonists have been developed to inhibit this receptor, as it is involved in a variety of diseases characterized by chronic inflammation. Unfortunately, all these antagonists lack clinical efficacy, and therefore a better understanding of their mechanism of action is warranted. In this study, we examined the pharmacological properties of small-molecule CCR2 antagonists in radioligand binding and functional assays. Six structurally different antagonists were selected for this study, all of which displaced the endogenous agonist 125I-CCL2 from CCR2 with nanomolar affinity. Two of these antagonists, INCB3344 [N-(2-(((3S,4S)-1-((1r,4S)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide] and CCR2-RA, were radiolabeled to study the binding site in greater detail. We discovered that [3H]INCB3344 and [3H]CCR2-RA bind to distinct binding sites at CCR2, the latter being the first allosteric radioligand for CCR2. Besides the binding properties of the antagonists, we examined CCR2 inhibition in multiple functional assays, including a novel label-free whole-cell assay. INCB3344 competitively inhibited CCL2-induced G protein activation, whereas CCR2-RA showed a noncompetitive or allosteric mode of inhibition. These findings demonstrated that the CCR2 antagonists examined in this study can be classified into two groups with different binding sites and thereby different modes of inhibition. We have provided further insights in CCR2 antagonism, and these insights are important for the development of novel CCR2 inhibitors.

22 January 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LHLaura Heitman
Laura Heitman
AGAnikó Göblyös
Anikó Göblyös
AZAnnelien M. Zweemer
Annelien M. Zweemer
RBRenée Bakker
Renée Bakker
TMThea Mulder-Krieger
Thea Mulder-Krieger
AIAd Ijzerman
Ad Ijzerman